Citadel Advisors
EVOK

Citadel Advisors’s Evoke Pharma EVOK Stock Holding History

Citadel Advisors’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-134
Closed -$11K – 13853
2021
Q4 		$11K Buy
+134
New +$18.7K ﹤0.01% 13662
2021
Q3 		– Sell
-358
Closed -$71K – 13996
2021
Q2 		$71K Buy
358
+41
+13% +$8.78K ﹤0.01% 13153
2021
Q1 		$83K Sell
317
-249
-44% -$99.6K ﹤0.01% 12613
2020
Q4 		$210K Sell
566
-347
-38% -$179K ﹤0.01% 9662
2020
Q3 		$617K Buy
+913
New +$582K ﹤0.01% 6913

Other funds holding EVOK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors's EVOK Position: Q3 2025 in Review

Citadel Advisors sold out of Evoke Pharma (EVOK) in Q3 2025, closing a stake of 12,542 shares — an estimated $33K sold.

Citadel Advisors first reported a position in EVOK in Q4 2016 and held it in 11 quarters. The position peaked at $108K in Q3 2020. 15 funds tracked by Wall St. Rank hold EVOK as of Q3 2025.

  • Citadel Advisors reported no remaining Evoke Pharma position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,542 Evoke Pharma shares in Q3 2025, an estimated $33K.
  • Citadel Advisors first reported a position in Evoke Pharma in Q4 2016 and held it in 11 quarters.
  • Citadel Advisors's Evoke Pharma position peaked at $108K in Q3 2020.
  • 15 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.